U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23ClN2O2
Molecular Weight 382.883
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORATADINE

SMILES

CCOC(=O)N1CCC(CC1)=C2C3=C(CCC4=C2N=CC=C4)C=C(Cl)C=C3

InChI

InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H23ClN2O2
Molecular Weight 382.883
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Curator's Comment: The second generation antihistamines were less soluble in lipid and thus less readily penetrated the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLARITIN

Approved Use

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat

Launch Date

7.3457277E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.1 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.8 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
96 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
34.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.4 h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Other AEs: Somnolence, Headache...
Other AEs:
Somnolence (10%)
Headache (9%)
Fatigue (5%)
Dry mouth (4%)
Sources:
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Other AEs: Fatigue, Fever...
Other AEs:
Fatigue (2%)
Fever (7%)
Headache (5%)
Influenza-like symptoms (2%)
Constipation (2%)
Diarrhea (3%)
Dyspepsia (2%)
Loose stools (2%)
Stomatitis (2%)
Tooth disorder (2%)
Vomiting (5%)
Earache (2%)
Drowsiness (7%)
Infection viral (2%)
Allergic rhinitis (2%)
Coughing (3%)
Epistaxis (3%)
Pharyngitis (3%)
Rash (2%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
n = 331
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 35.3
Sex: M+F
Population Size: 331
Sources:
Other AEs: Headache...
Other AEs:
Headache (4.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Somnolence 10%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Dry mouth 4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Fatigue 5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
n = 103
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 29
Sex: M+F
Population Size: 103
Sources:
Allergic rhinitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Constipation 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Dyspepsia 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Earache 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Fatigue 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Infection viral 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Influenza-like symptoms 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Loose stools 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Rash 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Stomatitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Tooth disorder 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Coughing 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Diarrhea 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Epistaxis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Pharyngitis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Headache 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Vomiting 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Drowsiness 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Fever 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
n = 60
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 3.6
Sex: M+F
Population Size: 60
Sources:
Headache 4.2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
n = 331
Health Status: unhealthy
Condition: seasonal allergic rhinitis
Age Group: 35.3
Sex: M+F
Population Size: 331
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
minor
minor
minor
minor
minor
minor
minor
minor
yes (co-administration study)
Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
1999 Dec
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
1999 Dec 15
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
1999 Jan
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats.
2000 Dec 22
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.
2000 Jan
Cetirizine and loratadine: a comparison using the ED50 in skin reactions.
2000 Mar-Apr
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
2001
Treatment of urticaria. An evidence-based evaluation of antihistamines.
2001
The pharmacologic profile of desloratadine: a review.
2001
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.
2001
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.
2001 Aug
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.
2001 Aug
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
2001 Jan
Triamcinolone: new and old indications.
2001 Jul
FDA panel recommends OTC status for second-generation antihistamines.
2001 Jul
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
2001 Jul-Aug
An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers.
2001 Mar
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
2001 Mar
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine.
2001 May
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus.
2001 May 11
Determination of loratadine in human plasma by high-performance liquid chromatographic method with ultraviolet detection.
2001 May 5
[Childhood asthma and viral infection: interactions and therapeutic possibilities].
2001 May-Jun
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
2001 Nov
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs).
2001 Nov 1
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.
2001 Nov 1
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.
2001 Nov 26
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.
2001 Oct
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.
2001 Oct
Do antihistamines impair school performance in children?
2001 Sep
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.
2001 Sep
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
2002
Clinical evidence for antileukotriene therapy in the management of allergic rhinitis.
2002 Apr
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
2002 Feb
Cardiotoxicity of new antihistamines and cisapride.
2002 Feb 28
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
2002 Jun
Which is more effective for as-needed treatment of seasonal allergy symptoms: intranasal corticosteroids or oral antihistamines?
2002 Mar
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
2002 Mar
Patents

Sample Use Guides

Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration: Oral
In Vitro Use Guide
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:25:11 UTC 2022
Edited
by admin
on Fri Dec 16 17:25:11 UTC 2022
Record UNII
7AJO3BO7QN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LORATADINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
SCH-29851
Code English
Loratadine [WHO-DD]
Common Name English
1-PIPERIDINECARBOXYLIC ACID, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-, ETHYL ESTER
Common Name English
LORATADINE [MART.]
Common Name English
LORATADINE [USP MONOGRAPH]
Common Name English
LORATADINE [EP MONOGRAPH]
Common Name English
LORATADINE [HSDB]
Common Name English
LORATADINE [MI]
Common Name English
LORATADINE COMPONENT OF CLARITIN-D
Common Name English
BAY76-2211
Code English
LORATADINE [USP-RS]
Common Name English
SCH 29851
Code English
LORATADINE [USAN]
Common Name English
ALAVERT
Brand Name English
CLARITIN-D COMPONENT LORATADINE
Common Name English
loratadine [INN]
Common Name English
NSC-758628
Code English
LORATADINE [ORANGE BOOK]
Common Name English
LORATADINE [VANDF]
Common Name English
LORATADINE [JAN]
Common Name English
CLARITIN
Brand Name English
LORATADINE [EP IMPURITY]
Common Name English
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate
Systematic Name English
Classification Tree Code System Code
WHO-ATC R06AX13
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
NCI_THESAURUS C29578
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
WHO-VATC QR06AX13
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
LIVERTOX NBK548831
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
Code System Code Type Description
EPA CompTox
DTXSID2023224
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
IUPHAR
7216
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
NSC
758628
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
INN
5864
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
CAS
79794-75-5
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
RS_ITEM_NUM
1370270
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
PUBCHEM
3957
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
MERCK INDEX
M6905
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY Merck Index
DRUG CENTRAL
1605
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
MESH
D017336
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
LACTMED
Loratadine
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
FDA UNII
7AJO3BO7QN
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
EVMPD
SUB08581MIG
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
HSDB
3578
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
USAN
W-119
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
RXCUI
28889
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY RxNorm
ChEMBL
CHEMBL998
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
DAILYMED
7AJO3BO7QN
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
DRUG BANK
DB00455
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
WIKIPEDIA
LORATADINE
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
NCI_THESAURUS
C29162
Created by admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
PRIMARY
Related Record Type Details
BINDER->LIGAND
METABOLIC ENZYME -> INHIBITOR
IC50
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT->INNOVATOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC